Psoriasis Patients with a History of Malignancy Represent an Important but Overlooked Study Population

The treatment of moderate to severe psoriasis often requires the administration of systemic agents. However, information is limited on the safety of systemic agents in patients with pre-existing cancers. We attempt to summarize the small body of data and urge organized study of this patient population.